SNDX Q1 2024 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$80M

Net Income

-$72M

EPS (Diluted)

$-0.85

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$84M

Free Cash Flow

-$84M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$543M

Total Liabilities

$51M

Stockholders' Equity

$492M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$80M	-$46M	-72.8%
Net Income	-$72M	-$41M	-76.0%